By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
A global pharmaceutical company with a strong focus on rare genetic diseases analyzed 8000 patients for a prospective real-world evidence (RWE) study.
Challenge
Centralization of unstructured data was an expensive undertaking that resulted in a lag between data collection and analysis.
Excel was the “gold” standard to collate, clean, analyze and report.
Security, confidentiality and privacy of data, sources and methods created regulatory and reputational risk.
Solution
Devron collaborated with rare disease data science/operations team to deploy/train models at the point of data generation across 5 research sights in 2 countries.
Devron’s encrypted model artifacts and repeated improvements in model accuracy accelerate analytics across all research sites.
Increases in speed and accuracy helped unlock predictive insights while curating portfolio ops efficiencies.